NCT03789604 - A Study of CS1001 in Subjects With Stage IV Non-Small Cell Lung Cancer | Biotech Hunter

Enrollment

479

Participants

Timeline

Start Date

December 13, 2018

Primary Completion Date

May 15, 2023

Study Completion Date

June 30, 2027

Conditions

Non Small Cell Lung Cancer

Interventions

BIOLOGICAL

CS1001 monoclonal antibody

Participant will receive CS1001 monoclonal antibody 1200 mg by intravenous infusion every 3 weeks, for up to 24 months; Drug Carboplatin on Day 1 of each 21-day cycle; Drug Pemetrexed on Day 1 of each 21-day cycle; Drug Paclitaxel on Day 1 of each 21-day cycle

BIOLOGICAL

CS1001 placebo

Participant will receive CS1001 placebo 1200 mg by intravenous infusion every 3 weeks, for up to 24 months; Drug Carboplatin on Day 1 of each 21-day cycle; Drug Pemetrexed on Day 1 of each 21-day cycle; Drug Paclitaxel on Day 1 of each 21-day cycle

Trial Locations (1)

Unknown

Shanghai Pulmonary Hospital, Shanghai